TransMedics Offers Inducement Grants for New Hires Under NASDAQ Guidelines

TransMedics Grant Inducements: A Strategic Move

TransMedics Group, Inc., a pioneer in organ transplant technology, is making headlines with its recent inducement grant announcements. As of May 19, 2026, the company has provided stock options and restricted stock units to new hires in line with NASDAQ Listing Rule 5635(c)(4). This move is designed to attract top talent in the competitive medical technology sector, particularly as the company continues to innovate in organ transplant therapies for patients facing severe health challenges.

Key Details of the Inducement Grant

On the specific date of the grant, TransMedics allocated a total of 37,367 stock options and 24,848 restricted stock units among 14 employees. A notable recipient includes Matthew S. Forsyth, the Senior Vice President and General Counsel, who received 23,171 stock options and 15,409 restricted stock units. Such incentives are critical for aligning employee interests with the long-term success of the company, affirming the board’s commitment to its workforce.

The stock options come with a per-share exercise price of $66.13, reflecting the closing price of TransMedics' shares on the Nasdaq Global Market. Employees will witness a vesting schedule where 25% of the stock options will become available on the first anniversary of their employment, with the remaining shares vesting monthly over the next three years—provided they remain employed by the company. This strategy is not only motivational but helps retain talent within the organization.

Understanding the Compensation Framework

The grants were approved by the Compensation Committee of TransMedics’ Board of Directors, reflecting a structured approach to employee compensation. Under the TransMedics Inducement Plan, the terms allow incentives that not only attract potential hires but also ensure that they align with the company's mission of improving transplant therapies. The stock options have a 10-year life span, which provides employees with a significant time to realize potential financial gains while contributing to the organizational goals.

For restricted stock units, the structure is similarly beneficial. They also vest at a rate of 25% on the anniversaries of the employees’ start dates, providing continued motivation and a sense of ownership as one’s tenure with the company progresses.

TransMedics and Its Mission

Founded in Andover, Massachusetts, TransMedics is known for its groundbreaking work in portable extracorporeal warm perfusion technology—essential in assessing and preserving donor organs for transplantation. By incessantly striving to increase the availability and quality of organs for transplantation, the company taps into a vital need in the healthcare industry. As they expand their team of skilled professionals, the recent grants underscore their ambition to not only enhance their operational capabilities but also ensure the highest standards in organ transplant technology.

Looking ahead, as TransMedics continues to delve deeper into the medical technology landscape, these inducement grants represent a pivotal strategy in securing top-notch talent, fortifying its commitment to innovation that saves lives.

For further inquiries or detailed financial information, interested parties may contact Brian Johnston or Hannah Jeffrey of TransMedics at 332-895-3222.